RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Cellular Biomedicine has been granted a Patent License for a next-gen neoantigen-reactive tumor infiltrating lymphocyte (TIL) technology from the National Cancer Institute of the US. The License gives CBMG non-exclusive, sub-licensable global rights to develop, manufacture and commercialize TIL technology. Financial details were not disclosed, nor did CMBG explain why the technology is “next-gen.” Headquartered in Silicon Valley, CBMG has operations in Shanghai and Beijing, where it develops immunotherapies for cancer and stem cell treatments for degenerative diseases.
Source: China Biotoday
